Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

(RTTNews) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN): Earnings: -$22.1 million in Q3 vs. -$61.3 million in the same period last year. EPS: -$0.24 in Q3 vs. -$0.75 in the same ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Stocks extended the post-election rally to new all-time highs early Thursday, a pull-back in bank stocks after Wednesday's surge higher saw the DJIA trading mildly weaker ahead midday. Earnings misses ...

Report Ocean has published a new report on the Cardiovascular Genetic Testing Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report ...

Another Trump term could spur Europe’s efforts to stand on its own, but it is far from clear its leaders will seize the moment this time. By Steven Erlanger Beijing is expecting more ...

Research Triangle Park-based Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been acquired by a small ophthalmic biopharmaceutical firm with ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...